How much funding has Theraly Fibrosis, Inc raised?

Theraly Fibrosis, Inc has raised $188.1M in total funding, most recently a Series B round.

Who are Theraly Fibrosis, Inc's investors?

Theraly Fibrosis, Inc's investors include Octave Life Sciences, Smilegate Investment, Praxis, InterVest Capital Partners, Magna Capital Partners, LB Investment.

When was Theraly Fibrosis, Inc founded?

Theraly Fibrosis, Inc was founded in 2017.

Where is Theraly Fibrosis, Inc headquartered?

Theraly Fibrosis, Inc is headquartered in Baltimore, Maryland, United States.

What industry is Theraly Fibrosis, Inc in?

Theraly Fibrosis, Inc operates in Biotech, Healthcare.

How many employees does Theraly Fibrosis, Inc have?

Theraly Fibrosis, Inc has 1-10 employees.

Theraly Fibrosis, Inc

디앤디파마텍

Baltimore, United States · Founded 2017 · $188.1M raised

Biotech

Healthcare

Headquarters: Baltimore, Maryland
Employees: 1–10
Founded: 2017
Business Model: B2G

Website: ddpharmatech.com
Total Funding: $188.1M
Last Round: $137.1M Series BAug 2024
Rounds: 2

About

Theraly Fibrosis is a preclinical-stage biopharmaceutical company developing TLY012, a recombinant human TRAIL protein that selectively targets myofibroblasts to reverse established fibrosis. The company's pipeline targets systemic sclerosis, chronic pancreatitis, liver fibrosis, and NASH, with two FDA Orphan Drug Designations granted for TLY012. Theraly is a subsidiary of D&D Pharmatech, a global clinical-stage biotech.

Summary

Theraly Fibrosis, Inc is a Biotech company based in Baltimore, United States, founded in 2017. It has raised $188.1M in total across 2 rounds, most recently a $137.1M Series B round in Aug 2024. Investors include Octave Life Sciences, Smilegate Investment and Praxis.